TILT-123 is under clinical development by TILT Biotherapeutics and currently in Phase I for Liposarcoma. According to GlobalData, Phase I drugs for Liposarcoma have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TILT-123’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TILT-123 overview
TILT-123 is under development for the treatment of metastatic melanoma, ovarian cancer, peritoneal cancer, sarcomas, non-small cell lung cancer, lung cancer and fallopian tube cancer,rectal carcinomas, gastriointestinal type carcinoma, pancreatic ductal adenocarcinoma, liposarcoma, SCCHN and refractory solid tumors. TILT-123 is a 5/3 chimeric serotype oncolytic adenovirus expressing human TNFalpha and human IL-2. TILT-123 is administered through intra-tumoral or intravenous route. The drug candidate is being developed as chimeric antigen receptor T cells for solid tumor.
It was also under development for the treatment of solid tumor.
TILT Biotherapeutics overview
TILT Biotherapeutics is a clinical-stage biotechnology company that provides the development of cancer therapeutics. The company pipeline products include TILT-123, and TILT-T610 for the treatment of ovarian cancer, TILT-123, TILT-T610 lung cancer, TILT-123, TILT-T215 melanoma, TILT-123, TILT-T776 head and neck cancer and melanoma, TILT-123, TILT-T115 solid tumors, TILT-452 solid tumors, TILT-321 and TILT-322 solid tumors, TILT-234 solid tumor. The company collaborates with industry leaders such as MSD. Merck KGaA, Darmstad for product development. TILT Biotherapeutics is headquartered in Helsinki, Finland.
For a complete picture of TILT-123’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
